Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure

Fig. 1

(Top) Calibration plots for the observed and predicted risk according to clinical markers, for A composite kidney (defined as the composite of sustained 40% decline of eGFR, end-stage kidney disease with eGFR < 15 mL/min/1.73 m², or need for dialysis or kidney transplantation, or kidney death); and B composite heart failure outcome in the CANVAS trial. (Bottom) Calibration plots for the observed and predicted risk according to clinical and novel biomarkers, for the C composite kidney and D composite heart failure outcome in the CANVAS trial

Back to article page